Bryan Garnier - SUMMIT THERAPEUTICS (SUMM.L) SUMMIT THERAPEUTICS: Summit Announces Increased BARDA Funding | CORPORATE | GBp157 (+530%)

Report

Bryan Garnier

Gary Waanders

SUMMIT THERAPEUTICS: Summit Announces Increased BARDA Funding | CORPORATE | GBp157 (+530%)

SUMMIT THERAPEUTICS - CORPORATE | GBp157 (+530%)
Summit Announces Increased BARDA Funding

New BARDA Funding Awarded
Use of BARDA Funding
Reiterating the Value

19/06/2019 3 EN

Underlying

SUMMIT THERAPEUTICS

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Gary Waanders

Other Reports on these Companies

ACF Equity Research

ACF Thematic Oncology Lung Cancer Cough LCC 25042025

Lung Cancer Cough (LCC) is an under-served, perhaps unserved therapeutic subsegment of the Lung Cancer/Oncology market. 57-65% of early diagnosis lung cancer patients suffer from LCC, it is a highly debilitating condition. The US lung cancer therapeutics market consensus values range from ~USD 29.9bn in 2023 to ~USD 71.3bn in 2034, suggesting a compound annual growth rate (CAGR) of 8.2% over our 10 year forecast period. LCC is a prevalent symptom among lung cancer patients, and its management is integral to patient care, however the mechanism of LCC is little researched and poorly understood. ...

April 29, 2025 April 29, 2025 1 EN

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

Fundamental Research

Feasibility Study Results in December to be a Catalyst for this Junior

EUR 17.58

November 25, 2019 November 25, 2019 14 EN

Lhyfe: EUR53m debt financing

Lhyfe yesterday announced that it has secured EUR53m debt financing for a portfolio of four green hydrogen projects. This transaction allows Lhyfe to complete the financing and refinance part of the investment already made in four units in France and Germany, with already operating and under develo

5h / 35m 5h / 35m 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Nel: poor Q1 results

This morning, Nel has reported Q1 2025 revenue at NOK155m (-63% QoQ, -44% YoY), 37% below cons. at NOK245m. The quarter was impacted by temporary production halts, with a significant slowdown in the alkaline division negatively impacting (-69% YoY) the scale and the revenue mix. EBITDA loss stood a

5h / 41m 5h / 41m 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

Abivax: ABTECT enrollment complete, induction topline data expected in Q3

Abivax's phase 3 ABTECT trials, evaluating obefazimod in patients with moderate-to-severe UC, has completed the enrolment of a total of 1,275 patients (exceeding the target enrollment by 4%). Baseline patient characteristics of the phase 3 closely aligns with the previous phase 2b in terms of %prio

5h / 47m 5h / 47m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN